Immunoregulatory Mechanisms Underlying Prevention of Colitis-Associated Colorectal Cancer by Probiotic Bacteria by Bassaganya-Riera, Josep et al.
Immunoregulatory Mechanisms Underlying Prevention of
Colitis-Associated Colorectal Cancer by Probiotic Bacteria
JosepBassaganya-Riera
1*,MonicaViladomiu
1,MireiaPedragosa
1,ClaudioDeSimone
2,RaquelHontecillas
1
1Nutritional Immunology and Molecular Medicine Laboratory, Center for Modeling Immunity to Enteric Pathogens, Virginia Bioinformatics Institute, Virginia Tech,
Blacksburg, Virginia, United States of America, 2Experimental Medicine, L’Aquila University, L’Aquila, Italy
Abstract
Background: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer. Probiotic bacteria produce
immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-
carcinogenic effects. This study aimed to investigate the cellular and molecular mechanisms underlying the efficacy of
probiotic bacteria in mouse models of cancer.
Methodology/Principal Findings: The immune modulatory mechanisms of VSL#3 probiotic bacteria and CLA were
investigated in mouse models of inflammation-driven colorectal cancer. Colonic specimens were collected for
histopathology, gene expression and flow cytometry analyses. Immune cell subsets in the mesenteric lymph nodes
(MLN), spleen and colonic lamina propria lymphocytes (LPL) were phenotypically and functionally characterized. Mice
treated with CLA or VSL#3 recovered faster from the acute inflammatory phase of disease and had lower disease severity in
the chronic, tumor-bearing phase of disease. Adenoma and adenocarcinoma formation was also diminished by both
treatments. VSL#3 increased the mRNA expression of TNF-a, angiostatin and PPAR c whereas CLA decreased COX-2 levels.
Moreover, VSL#3-treated mice had increased IL-17 expression in MLN CD4+ T cells and accumulation of Treg LPL and
memory CD4+ T cells.
Conclusions/Significance: Both CLA and VSL#3 suppressed colon carcinogenesis, although VSL#3 showed greater anti-
carcinogenic and anti-inflammatory activities than CLA. Mechanistically, CLA modulated expression of COX-2 levels in the
colonic mucosa, whereas VSL#3 targeted regulatory mucosal CD4+ T cell responses.
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Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer in the United States [1]. An estimated 50,000 deaths are
attributed to CRC around the world each year [2]. Together with
the hereditary syndromes of familial adenomatous polyposis and
hereditary nonpolyposis, inflammatory bowel disease (IBD) is
among the top three high-risk conditions for CRC [3]. Among
ulcerative colitis (UC) patients, one of the two main manifestations
of IBD, the relative risk of developing CRC correlates with the
extent and duration of disease [3,4]. In patients with IBD, this risk
increases by 0.5–1.0% yearly after 8–10 years [5].
The human gut microflora, which contains about 100 trillion
microbial organisms, plays a critical role in maintaining host health,
both in the gastrointestinal tract and systemically through the
absorption of metabolites (e.g. vitamins and short chain fatty acids)
[6].Recentstudieshavedemonstratedthatspecificstrainsofbacteria
are implicated in the regulation of the intestinal homeostasis,
delivering regulatory signals to the epithelium, the mucosal immune
system and to the neuromuscular activity of the gut [7,8]. Moreover,
some commensal and pathogenic organisms of the human enteric
microbiome are essential in the pathogenesis of IBD and CRC.
Therefore, manipulating the gut bacterial composition and local
metabolite production by using probiotic bacteria has been explored
as a promising avenue for therapeutic intervention against CRC.
Probiotics are live microbial feed supplements which beneficially
impact on host health. They rely on introducing particular
exogenous strains into the gut microflora [8,9]. These strains are
often chosen for specific beneficial activities, like the production of
lipids such as conjugated linoleic acid (CLA) and conjugated linoleic
acidisomers (CLNA)[10,11].These lipidsvaryin chemical structure
from short fatty acids such as propionate, acetate and butyrate to
polyunsaturated fatty acids (PUFA) and are involved in regulating
apoptosis and the immune response [10,12–14].
Ascreeningof36differentBifidobacteriumstrainsfortheirability
to produce CLA from free linoleic acid and CLNA from alpha-
linolenic acid (LNA) reveals that six strains (four Bifidobacterium breve
strains, a B. bifidum strain and a B. pseudolongum strain) are able to
produce different CLA and CLNA isomers in vitro [15]. Others have
shown that probiotic bacteria can synthesize CLA [16–18]. CLA-
producingbacterialstrains canbe found ina commerciallyavailable
probiotic formulation known as VSL#3. This product is composed
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34676of four strains of lactobacilli (Lactobacillus casei, L. plantarum, L.
bulgaricus, and L. acidophilus), three strains of bifidobacteria
(Bifidobacterium longum, B. breve, and B. infantis) and Streptococcus
thermophilus. Recently, we have demonstrated that VSL#3 probiotic
bacteria produce CLA locally that targets macrophage peroxisome
proliferator-activated receptor (PPAR) c to suppress colitis [19]. In
addition, VSL#3 may play a key role in maintaining the intestinal
microbial balance by synthesizing antibacterial substances like
lantibiotics [20], and other bacteriocin-like compounds [21].
Moreover, VSL#3 treatment is associated with a down-regulation
of LPS-activated IL-8 production and suppressed secretion of TNF-
a and IFN-c [22]. These immunoregulatory actions are consistent
with activation of PPAR c by the gut microflora following VSL#3
probiotic treatment. The objective of this study is to investigate the
ability of VSL#3 bacteria to modulate mucosal immune responses
and thereby ameliorate colonic carcinogenesis.
Materials and Methods
Animal procedures and experimental diets
C57BL/6 wild-type mice (n=60) were used for DSS-induced
CRC study. In a follow up study, we also used IL-10-deficient (IL-
102/2) and wild-type mice in a 129/SvEv background (n=60).
For each experiment, mice were fed purified AIN-93G rodent
diets (Table S1) with or without 1% CLA for 24 days prior the
induction of inflammation-related cancer, in which all the
requirements where met or exceeded. The CLA supplement
administered contained a 50:50 mixture of the cis-9, trans-11 CLA
and trans-10, cis-12 isomers (Clarinol, Loders Croklaan BV).
Ethics Statement
All experimental procedures were approved by the Virginia
Tech Institutional Animal Care and Use Committee (IACUC) and
met or exceeded requirements of the Public Health Service/
National Institutes of Health and the Animal Welfare Act.
Oral treatment with probiotic bacteria
For each experiment, approximately half of the mice received
0.5 mL of the VSL#3 probiotic solution daily by orogastric gavage
using a ball tip gavage needle. The probiotic solution was freshly
prepared daily in phosphate buffered saline (PBS) at pH 7.1 in
sterile conditions to a final concentration of 0,0072 g VSL#3/mL,
correspondingto 1.2billionbacteria permouse/day,a dose that has
shown efficacy in colonizing the colon and terminal ileum [23,24].
Further, this dose is biologically relevant since it is based on a daily
intake of about 3,600 billion bacteria for an adult human weighing
70 kg. VSL#3 is a commercial probiotic mixture composed of four
strains of lactobacilli (Lactobacillus casei, L. plantarum, L. bulgaricus,a n d
L. acidophilus), three strains of bifidobacteria (Bifidobacterium longum, B.
breve, and B. infantis) and Streptococcus thermophilus.
Colorectal cancer induction
A previously established protocol was followed to chemically
induce inflammation-driven CRC [25,26]. Wild type mice were
challenged with azoxymethane (10 mg/kg) on week 6 of the study,
followed by a 2.0% dextran sodium sulfate (DSS) treatment in the
drinking water for 7 daysbeginning on week 7.IL-10-deficient 129/
SvEv mice were challenged with a single dose of 5610
7 cfu
Helicobacter typhlonius by oral gavage to accelerate colon carcinogen-
esis as previously shown [27]. Disease activity indices and rectal
bleeding scores were calculated using a modification of a previously
published compounded score [28]. Mice were euthanized at the
moment of tumor formation, corresponding to day 68 (C57BL/6
strain) or day 18 after infection with H. typhlonius (129/SvEv strain).
Histopathology
Colonic sections were fixed in 10% buffered neutral formalin,
later embedded in paraffin, and then sectioned (6 mm) and stained
withH&Eforhistologicalexamination.Tissueslideswereexamined
in an Olympus microscope (Olympus America Inc., Dulles, VA).
Colons were scored for leukocyte infiltration, epithelial erosion,
mucosal thickness, adenocarcinomas and adenomas.
RNA isolation and real-time polymerase chain reaction of
cytokines
Total RNA from colon was isolated using the Qiagen RNA
isolation kit (Qiagen) according to the manufacturer’s instructions,
and then was used to generate the cDNA template using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and real-time
RT-PCR was performed as previously described [12].
Immunophenotyping
Spleen and mesenteric lymph nodes (MLN) were excised and
single-cell suspensions of tissues were resuspended in PBS and
enumerated with the Coulter Counter (Beckman Coulter, Full-
erton, CA). Colon samples were processed for lamina propria
lymphocyte (LPL) isolation. Specifically, cells (6610
5 cells/well)
were seeded into 96 well-plates, centrifuged at 4uC at 3000 rpm
for 3 minutes, and washed with PBS containing 5% serum and
0,09% sodium azide (FACS buffer). Cells were then incubated for
macrophage assessment with fluorochrome-conjugated primary
antibodies to T cell and macrophage markers.
Statistical analysis
To determine the statistical significance of the model, analysis of
variance (ANOVA) was performed using the general linear model
procedure of Statistical Analysis Software (SAS), and probability
value (P),0.05 was considered to be significant. When the model
was significant, ANOVA was followed by Fisher’s Protected Least
Significant Difference multiple comparison method.
Results
VSL#3 and CLA ameliorate disease activity in mice with
CRC
In both models, VSL#3 and CLA treatments decreased disease
activity scores associated with colitis-associated CRC in compar-
ison to the untreated control group. In the azoxymethane-induced
CRC model, mice treated with either CLA or VSL#3 recovered
faster from the acute inflammatory phase of disease (days 1–26)
and had lower disease severity in the chronic, tumor-bearing phase
of disease (days 63–68). Overall, VSL#3 probiotic bacteria
treatment was more effective than CLA in decreasing inflamma-
tion and reducing disease activity in both models (Figure 1A and
Figure 2A). In line with these clinical findings, VSL#3 and CLA
significantly ameliorated gross pathology in colon, spleen and
MLN in comparison to untreated control mice in the azoxy-
methane induced CRC (Figure 1B–C). In the IL102/2 model,
the probiotic mixture VSL#3 but not CLA decreased inflamma-
tion-related lesions in MLN, colon and spleen of H. typhlonius
infected mice in comparison to the control group (Figure 2B–D).
VSL#3 and CLA prevent colonic histological lesions in
mice with CRC
Regarding the azoxymethane/DSS colitis-associated CRC mod-
el, CLA treatment, but not VSL#3 administration, decreased
leukocyte infiltration and colonic mucosal thickness (Figure 3 A&B).
Interestingly, VSL#3 was more effective than CLA in reducing
Colorectal Cancer Prevention by Probiotics
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infectedwithH.typhlonius(Figure4A&B).Additionally,bothVSL#3
and CLA treatments diminished adenoma and adenocarcinoma
formation when compared to the control. These results were
consistent for both CRC models (Figure 3 C&D and Figure 4 C&D).
VSL#3 and CLA modulate expression of colonic
inflammatory and carcinogenesis markers
Mice challenged with azoxymethane and DSS were euthanized
in the tumor-bearing phase of the disease. Those mice treated with
either CLA or VSL#3 showed an increased mRNA expression of
CD36 and PPAR c. in the colon (Figure 5 A&C). In addition, oral
CLA administration significantly down-regulated colonic COX-2
expression (Figure 5B) whereas VSL#3 treatment upregulated
angiostatin mRNA levels in the distal colon (Figure 5D), a
proteolytic fragment of plasminogen with anti-angiogenic effects in
mice with CRC. Finally, an upregulation of colonic TNF-a was
found in CLA and VSL#3-treated mice when compared to the
untreated control group (data not shown).
VSL#3 and CLA modulate phenotype and cytokine
production of macrophages and CD4+ T cell subsets in
the MLN and colonic LP
Those healthy mice that received VSL#3 had greater
percentages of IL-17-expressing CD4+ T cells in MLN when
compared to the untreated control group (Figure 6A). Similarly,
CLA treatment increased the population of IL-17-expressing
CD4+ T cells in the spleen of both healthy and CRC
mice (Figure 6B). Greater percentages of CD4
+FoxP3
+ and
CD4
+CD44
+CD62L
+ LP T cells, corresponding to mucosal
regulatory T cells (Treg) and CD4
+ memory T cells respectively,
were found in VSL#3-treated mice (Figure 6C&D).
Discussion
Chronic intestinal inflammation occurring in IBD induces
persistent damage and enhanced mucosal permeability along the
gastrointestinal tract, playing an important role in the develop-
ment of colorectal cancer (CRC) [29]. Manipulation of colonic
bacteria with probiotics has been shown to be effective in the
regulation of gut homeostasis in part through production of
bacterial metabolites [30]. VSL#3 probiotic bacteria can produce
CLA locally in the gut, a compound that down-modulates
inflammatory responses by activating PPAR c [31]. In addition,
CLA prevents or ameliorates experimental IBD in mice and pigs
[12,13,32]. Moreover, PPAR c agonists have shown clinical
efficacy against human UC [33,34]. Recently, we demonstrated
that the probiotic mixture VSL#3 suppresses intestinal inflam-
mation by producing CLA locally in the colon and activating
PPAR c in macrophages [19]. This study aimed to investigate the
mechanisms of CLA and VSL#3 in mouse models of colitis-
associated CRC.
The clinical response in the AOM/DSS model had a bimodal
distribution in which the first peak corresponded to acute
inflammation due to the DSS challenge followed by a period of
clinical recovery characterized by lower chronic inflammation.
The second peak of disease appeared on day 48 corresponding to
the tumor formation. This pattern is consistent with results of
previous studies from our group that characterized the anti-
Figure 1. Effect of VSL#3 and dietary conjugated linoleic acid (CLA) supplementation on experimental azoxymethane-induced
colorectal cancer. C57BL/6J mice (n=60) were treated with the VSL#3 probiotic (n=20), CLA-supplemented (1 g/100 g) (n=20) or control diets
(n=20) for 32 days and challenged i.p. with azoxymethane (10 mg/kg) followed by 2% dextran sodium sulfate (DSS) in the drinking water for 7 days
to induce colitis-associated colorectal cancer (CRC). The disease activity index, a composite score reflecting clinical signs of the disease (i.e. perianal
soiling, rectal bleeding, diarrhea, and piloerection) was assessed daily for mice undergoing the DSS challenge (A). Mice were euthanized on day 68.
Colon and mesenteric lymph nodes (MLN) (B&C) were macroscopically scored for inflammation. Data are represented as mean 6 standard error.
Points with an asterisk are significantly different when compared to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34676Figure 2. Effect of VSL#3 and dietary conjugated linoleic acid (CLA) supplementation on experimental Helicobacter typhlonius-
induced colorectal cancer. Bacterial-free 129/SvEv and IL-10 gene deficient (IL-102/2) 129/SvEv mice in a 129/SvEv background (n=60) were
treated with the VSL#3 probiotic (n=20), CLA-supplemented (1 g/100 g) (n=20) or control diets (n=20) for 32 days and then were infected with H.
typhlonius in order to develop experimental colorectal cancer associated with colitis. The disease activity index, a composite score reflecting clinical
signs of the disease, was assessed daily for mice undergoing the DSS challenge (A). Colon, spleen and mesenteric lymph nodes (MLN) (B–D) were
macroscopically scored for inflammation. Data are represented as mean 6 standard error. Points with an asterisk are significantly different when
compared to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g002
Figure 3. Effect of the CLA and VSL#3 treatment on colon histopathology on experimental azoxymethane-induced colorectal
cancer. C57BL/6J mice (n=60) were treated with the VSL#3 probiotic (n=20), CLA-supplemented (1 g/100 g) (n=20) or control diets (n=20) for 32
days and challenged i.p. with azoxymethane (10 mg/kg) followed by 2% dextran sodium sulfate (DSS) in the drinking water for 7 days to induce
colitis-associated colorectal cancer (CRC). Mice were euthanized on day 68. All specimens underwent blinded histological examination and were
scored 1–4 on leukocyte infiltration (A), and mucosal wall thickening (B), adenocarcinomas (C) and adenomas (D). Data are represented as mean 6
standard error. Points with an asterisk are significantly different when compared to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34676Figure 4. Effect of the CLA and VSL#3 treatment on colon histopathology on experimental Helicobacter typhlonius-induced
colorectal cancer. Bacterial-free 129/SvEv and IL-10 gene deficient (IL-102/2) 129/SvEv mice in a 129/SvEv background (n=60) were treated with
the VSL#3 probiotic (n=20), CLA-supplemented (1 g/100 g) (n=20) or control diets (n=20) for 32 days and then were infected with H. typhlonius in
order to develop experimental colorectal cancer associated with colitis. After the necropsy, all specimens underwent blinded histological examination
and were scored 1–4 on mucosal wall thickening (A), leukocyte infiltration (B), adenomas (C) and adenocarcinomas (D). Data are represented as mean
6 standard error. Points with an asterisk are significantly different when compared to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g004
Figure 5. VSL#3 and conjugated linoleic acid (CLA) modulate colonic gene expression. C57BL/6J mice (n=60) were treated with the
VSL#3 probiotic (n=20), CLA-supplemented (1 g/100 g) (n=20) or control diets (n=20) for 32 days and challenged i.p. with azoxymethane (10 mg/kg)
followed by 2% dextran sodium sulfate (DSS) in the drinking water for 7 days to induce colitis-associated colorectal cancer (CRC). Mice were euthanized
on day 68. Expression of CD36 (A), cyclooxygenase 2 (COX2) (B), peroxisome proliferator-activated receptor c (PPAR c) (C) and angiostatin (D) were
assessedbyreal-timequantitativePCR. Dataarerepresentedasmean 6standarderror.Pointswith anasterisk aresignificantly differentwhen compared
to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g005
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mice also showed lower macroscopic inflammation-related lesions
and significantly improved colonic histopathology in both
experimental models. Nevertheless, while VSL#3 was the
compound that prevented tumor formation most effectively, it
did not prevent leukocyte infiltration in comparison to the other
groups in the azoxymethane-induced colorectal cancer model,
suggesting a possible role of infiltrating leukocytes in the anti-
carcinogenic actions of VSL#3. In a follow up study, using a
different model of colitis-associated colonic carcinogenesis, IL-
102/2 mice in a 129/SvEv background were infected with H.
typhlonius, thus accelerating the colonic inflammation that the
IL102/2 develop spontaneously and promoting colonic carcino-
genesis [27]. In this model, both VSL#3 and CLA ameliorated
disease severity but only the probiotic mixture was effective in
reducing inflammation-related lesions in MLN, spleen and colon.
This consistency of results in both models demonstrates that the
efficacy of VSL#3 in restoring mucosal homeostasis and
attenuating colitis-associated CRC is not model-dependent.
Our gene expression analyses showed an upregulation of colonic
TNF-a in CLA and VSL#3-treated mice when compared to the
untreated control group, which may be indicative of immuno-
stimulation and enhanced epithelial healing ability. Most notably,
TNF-a exerts potent antitumoral effects by stimulating immune
responses, including upregulation of human leukocyte antigen
antigens in tumor cell surfaces [35], enhanced cytotoxicity [36]
stimulation of cytotoxic T cells and natural killer (NK) cells [37–
40] as well as epithelial healing [41]. In addition, CLA-treated
mice showed a significantly reduced expression of cyclooxygenase-
2 (COX-2), an enzyme involved in arachidonic acid cascade and
prostaglandin-mediated inflammation. Previous studies have
suggested the suppressive effects of CLA on colon carcinogenesis
due to changes in this cascade and in the activation of PPAR c,
both mechanisms involving the inhibition of COX-2 expression
and inducing apoptosis [42,43]. The levels of angiostatin, a
proteolytic fragment of plasminogen and an endogenous inhibitor
of angiogenesis [44], were greater in the VSL#3 group when
compared to control fed mice, suggesting that the anti-carcino-
genic actions of VSL#3 may be mediated, in part, by suppressed
angiogenesis. As shown in previous studies [45,46], this inhibitory
behavior of angiostatin on angiogenesis could be indirectly related
with anti-carcinogenic efficacy. Our findings extend the findings of
a recent report demonstrating that probiotic VSL#3 can attenuate
chronic inflammation in rats, delaying the transition from
inflammation to dysplasia and cancer [47].
The ability of VSL#3 and CLA to modulate immune responses
and prevent CRC was also assessed by examining the distribution
of immune cell subsets at the colonic mucosa and systemically.
VSL#3 treatment enhanced the percentages of IL-17-expressing
CD4+ T cells in the mucosal inductive site (i.e., MLN) and Foxp3-
expressing CD4+ T cells in the effector site in mice with CRC,
suggesting a possible role in modulating the plasticity between
Th17 and Treg in the MLN and colonic LP. Results from a recent
study identified segmented filamentous bacteria in the gut
commensal microbiota as inducers of the Th17 polarization in
the gut mucosa [48]. It is tempting to speculate that changes in the
composition of the colon microbiome triggered by probiotic
bacteria may exert similar effects. In conclusion, our data
demonstrate the ability of CLA and VSL#3 to ameliorate
inflammation-induced colorectal cancer through a mechanism
Figure 6. VSL#3 and conjugated linoleic acid (CLA) modulate immune cell subsets in mesenteric lymph nodes (MLN), colonic
lamina propria lymphocytes (LPL) and spleen. C57BL/6J mice (n=60) were treated with the VSL#3 probiotic (n=20), CLA-supplemented (1 g/
100 g) (n=20) or control diets (n=20) for 32 days and challenged i.p. with azoxymethane (10 mg/kg) followed by 2% dextran sodium sulfate (DSS) in
the drinking water for 7 days to induce colitis-associated colorectal cancer (CRC). Mice were euthanized on day 68. MLN (A–C), spleen (D) and LPL (E–
F) from wild type mice were immunophenotyped to identify immune cells subsets by flow cytometry. Data are represented as mean 6 standard
error. Points with an asterisk are significantly different when compared to the control group (P,0.05).
doi:10.1371/journal.pone.0034676.g006
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modulation of gene expression.
Supporting Information
Table S1 Composition of experimental diets.
1 Per kg
diet: 3 g nicotinic acid, 1.6 g calcium pantotenate, 0.7 g
pyridoxine HCl, 0.6 g thiamin HCl, 0.6 g riboflavin, 0.2 g folic
acid, 0.02 g D-biotin, 2.5 g vitamin B-12 (0.1% in mannitol), 15 g
d,l-a tocopheryl acetate (500 IU/g), 0.8 g vitamin A palmitate
(500,000 IU/g), 0.2 g cholecalciferol (500,000 IU/g), 0.075 g
vitamin K (phylloquinone), and 974.705 g sucrose.
2 Per kg diet:
357 g calcium carbonate, 196 g potassium phosphate monobasic,
70.78 g potassium citrate, 74 g sodium chloride, 46.6 g potassium
sulfate, 24.3 g magnesium oxide, 6.06 g ferric citrate, 1.65 g zinc
carbonate, 0.63 g manganous carbonate, 0.31 g cupric carbonate,
0.01 g potassium iodate, 0.01025 g sodium selenate, 0.00795 g
ammonium paramolybdate, 1.45 g sodium meta-silicate, 0.275 g
chromium potassium sulfate, 0.0174 g lithium chloride, 0.0815 g
boric acid, 0.0635 g sodium fluoride, 0.0318 g nickel carbonate,
hydroxide, tetrahydrate, 0.0066 g ammonium vanadate, and
220.716 g sucrose.
3Antioxidant.
(DOCX)
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